Lipocine Inc.

Lipocine Inc. is a U.S.-based biopharmaceutical company developing oral drug-delivery products built on a proprietary lipid-based technology platform. Its programs target hard-to-deliver molecules across testosterone replacement, CNS disorders, liver disease, and women’s health, with TLANDO as its approved commercial product and the rest of the pipeline still in development.

−521,6 %

−487,1 %

−82,3 %

6.68

6.68

— Lipocine Inc.
%
Commercial product25% Approved oral testosterone replacement therapy marketed through license partners.
CNS pipeline35% Oral neuroactive steroid candidates for postpartum depression, MDD, and epilepsy.
Liver disease pipeline15% Programs aimed at decompensated cirrhosis and prevention of overt hepatic encephalopathy.
Women’s health pipeline15% Development assets focused on postpartum depression and pre-term birth.
Licensing and collaboration revenue10% Upfront, milestone, royalty, and research-support income from partners.

Lipocine sells primarily through licensing and commercialization partners rather than direct hospital or retail...

  • Territory license partnersprimary

    Verity, SPC, Pharmalink, and Aché commercialize TLANDO in their territories and pay milestones/royalties.

  • Prescribing physiciansprimary

    Endocrinology, urology, psychiatry, neurology, and hepatology prescribers choose oral options for patients.

  • Patientsprimary

    Men and women seeking oral therapies that may improve convenience, adherence, and tolerability.

  • Development partnerssecondary

    Potential collaborators for LPCN 1148, LPCN 2401, LPCN 1107, LPCN 1154, LPCN 2201, and LPCN 2101.

  • Service providerssecondary

    CROs and contract manufacturers that support clinical trials and drug production.

Lipocine is headquartered and primarily operated from Salt Lake City, Utah, with most employees based there...

  • •Headquarters and main operations in Salt Lake City, Utah
  • •Most employees work from the Salt Lake City facility
  • •Revenue comes mainly from partner territories via licensing and royalties
  • •No direct product sales yet; commercialization depends on approvals
  • •Future expansion outside current territories is a strategic option

Lipocine’s strategy is to use its oral drug-delivery platform to create differentiated products for large unmet medical...

01
Support TLANDO partner commercializationshort-term

Royalty and milestone income depends on partner execution and market uptake.

02
Advance CNS pipeline candidatesmedium-term

These programs could create future value if clinical data and regulatory progress are positive.

03
Pursue partnerships for non-core assetsmedium-term

Partnerships reduce funding burden and broaden development reach.

04
Maintain IP and operating flexibilityshort-term

Patent protection and lean overhead are critical for a small development-stage biotech.

Lipocine remains a development-stage biotech with heavy dependence on clinical outcomes, FDA review, and partner...

high

Clinical development failure

Pipeline assets are early stage and depend on positive trial results to support NDA filings and approvals.

Scope
LPCN 1154, LPCN 2201, LPCN 2101, LPCN 1148, LPCN 2401, LPCN 1107
Materiality
high
high

Regulatory approval risk

The company may not receive FDA approval or approval outside the U.S. for product candidates.

Scope
All pipeline programs and future geographic expansion
Materiality
high
high

Partner commercialization risk

TLANDO revenue depends on third-party licensees successfully marketing and distributing the product.

Scope
Verity, SPC, Pharmalink, Aché territories
Materiality
high
high

Financing risk

The company expects to need additional capital through equity, debt, or partnering.

Scope
Operating runway and clinical development budget
Materiality
high
medium

Third-party dependence

CROs and contract manufacturers perform substantial trial and manufacturing work.

Scope
Clinical timelines, supply continuity, quality control
Materiality
medium
Revenue recognition under partner agreements
Affects reported revenue timing and comparability
Royalty revenue from TLANDO sales
Creates quarter-to-quarter revenue volatility
R&D expense estimation
Can change operating loss and cash burn
Lease accounting
Affects operating expense and balance sheet liabilities

LB PHARMACEUTICALS INC

LBRX · Pharmaceutical Preparations

Aptose Biosciences Inc.

APTOF · Biological Products, (No Diagnostic Substances)

BIOVIE INC.

BIVI · Pharmaceutical Preparations

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

Tectonic Therapeutic, Inc.

TECX · Biological Products, (No Diagnostic Substances)

FILANA THERAPEUTICS, INC.

FLNA · Pharmaceutical Preparations

: 28/04/2026